offline
AbbVie (ABBV) Q4 Earnings and Revenues Beat Estimates
AbbVie (ABBV) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.20 per share. This compares to earnings of $1.90 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.45%. A quarter ago, it was expected that this drugmaker would post earnings of $2.29 per share when it actually produced earnings of $2.33, delivering a surprise of 1.75%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.70 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.03%. This compares to year-ago revenues of $8.31 billion.
...
https://finance.yahoo.com/news/abbvie-ab...02013.html
![[Bild: ABBVc1dl1018.png]](https://finviz.com/publish/020820/ABBVc1dl1018.png)
AbbVie (ABBV) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.20 per share. This compares to earnings of $1.90 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.45%. A quarter ago, it was expected that this drugmaker would post earnings of $2.29 per share when it actually produced earnings of $2.33, delivering a surprise of 1.75%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.70 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.03%. This compares to year-ago revenues of $8.31 billion.
...
https://finance.yahoo.com/news/abbvie-ab...02013.html
__________________
